Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.

Abstract

Tizanidine, an imidazoline that acts as an agonist at alpha 2-adrenergic receptors, has been shown to be effective in reducing spasticity caused by MS. This multicenter study (14 sites) assessed the efficacy and safety of oral tizanidine in patients who had spinal cord injury of > 12 months' duration. Of the 124 patients admitted to the study, 78 completed it. Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d. Muscle tone, assessed by Ashworth score, was significantly reduced (p = 0.0001) by tizanidine treatment in comparison with placebo. Video motion analysis of the pendulum test showed improvement in the tizanidine-treated patients vs placebo (p = 0.04) and showed a significant correlation with the Ashworth score (p < 0.001). No significant alterations in muscle strength or vital signs were noted in either treatment group. The most common adverse events during tizanidine treatment were somnolence, xerostomia, and fatigue. It was concluded that, overall, tizanidine is effective in reducing spasticity in patients with spinal cord injury.

Links

  • Aggregator Full Text
  • Authors+Show Affiliations

    ,

    Section of Physical Medicine and Rehabilitation, University of Manitoba, Winnipeg, Canada.

    , , ,

    Source

    Neurology 44:11 Suppl 9 1994 Nov pg S44-51; discussion S51-2

    MeSH

    Activities of Daily Living
    Administration, Oral
    Adolescent
    Adult
    Aged
    Clonidine
    Female
    Humans
    Male
    Middle Aged
    Muscle Relaxants, Central
    Muscle Spasticity
    Muscle Tonus
    Spasm
    Spinal Cord Injuries

    Pub Type(s)

    Clinical Trial
    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    7970010

    Citation

    Nance, P W., et al. "Efficacy and Safety of Tizanidine in the Treatment of Spasticity in Patients With Spinal Cord Injury. North American Tizanidine Study Group." Neurology, vol. 44, no. 11 Suppl 9, 1994, pp. S44-51; discussion S51-2.
    Nance PW, Bugaresti J, Shellenberger K, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S44-51; discussion S51-2.
    Nance, P. W., Bugaresti, J., Shellenberger, K., Sheremata, W., & Martinez-Arizala, A. (1994). Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology, 44(11 Suppl 9), pp. S44-51; discussion S51-2.
    Nance PW, et al. Efficacy and Safety of Tizanidine in the Treatment of Spasticity in Patients With Spinal Cord Injury. North American Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S44-51; discussion S51-2. PubMed PMID: 7970010.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. AU - Nance,P W, AU - Bugaresti,J, AU - Shellenberger,K, AU - Sheremata,W, AU - Martinez-Arizala,A, PY - 1994/11/1/pubmed PY - 1994/11/1/medline PY - 1994/11/1/entrez SP - S44-51; discussion S51-2 JF - Neurology JO - Neurology VL - 44 IS - 11 Suppl 9 N2 - Tizanidine, an imidazoline that acts as an agonist at alpha 2-adrenergic receptors, has been shown to be effective in reducing spasticity caused by MS. This multicenter study (14 sites) assessed the efficacy and safety of oral tizanidine in patients who had spinal cord injury of > 12 months' duration. Of the 124 patients admitted to the study, 78 completed it. Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d. Muscle tone, assessed by Ashworth score, was significantly reduced (p = 0.0001) by tizanidine treatment in comparison with placebo. Video motion analysis of the pendulum test showed improvement in the tizanidine-treated patients vs placebo (p = 0.04) and showed a significant correlation with the Ashworth score (p < 0.001). No significant alterations in muscle strength or vital signs were noted in either treatment group. The most common adverse events during tizanidine treatment were somnolence, xerostomia, and fatigue. It was concluded that, overall, tizanidine is effective in reducing spasticity in patients with spinal cord injury. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/7970010/Efficacy_and_safety_of_tizanidine_in_the_treatment_of_spasticity_in_patients_with_spinal_cord_injury__North_American_Tizanidine_Study_Group_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=7970010.ui DB - PRIME DP - Unbound Medicine ER -